`Patent 8,791,154
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`ARGENTUM PHARMACEUTICALS LLC,
`APOTEX INC., and APOTEX CORP.,
`Petitioners,
`
`v.
`
`ALCON RESEARCH, LTD,
`Patent Owner
`__________________
`
`Patent No. 8,791,154
`Issue Date: July 29, 2014
`Title: HIGH CONCENTRATION OLOPATADINE
`OPHTHALMIC COMPOSITION
`__________________
`
`Inter Partes Review No. 2016-005441
`__________________
`
`
`STIPULATION CONCERNING SCHEDULE
`
`
`
`
`
`
`
`
`1 Petitioners Apotex Inc. and Apotex Corp. from IPR2016-01640 have been joined
`as Petitioners to this proceeding.
`
`
`
`
`
`
`
`Petitioner Argentum Pharmaceuticals LLC (“Argentum”) and Patent Owner
`
`Case IPR 2016-00544
`Patent 8,791,154
`
`
`
`Alcon Research, Ltd. (“Alcon”) have conferred, and hereby stipulate and agree as
`
`follows:
`
`1.
`
`Due Date 1 is extended to December 2, 2016, for the purpose of
`
`Alcon submitting its patent owner response to Argentum’s petition.
`
`2.
`
`Due Date 2 is extended to March 6, 2017, for the purpose of
`
`Argentum submitting its reply to Alcon’s response to Argentum’s petition.
`
`3.
`
`All other Due Dates set forth in Paper 9, dated July 18, 2016, and the
`
`Stipulation Concerning Schedule, dated October 3, 2016, remain as stated therein.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Michael R. Houston (with permission)/
`Michael R. Houston, Ph.D.
`Reg. No. 58,486
`Lead Counsel for Petitioner
`Argentum Pharmaceuticals, LLC
`
`Foley & Lardner LLP
`3000 K St. N.W., Suite 600
`Washington, D.C. 20008
`312-832-4378 (Telephone)
`608-257-5035 (Facsimile)
`jmeara-PGP@foley.com
`
`
`
`
`
`
`
`
`
`
`Date: October 27, 2016
`
`/David M. Krinsky/
`David M. Krinsky
`Reg. No. 72,339
`
`Lead Counsel for
`
`Patent Owner
`
`
`Williams & Connolly LLP
`725 Twelfth St., N.W.
`
`Washington, D.C. 20005
`202-434-5338 (Telephone)
`202-434-5029 (Facsimile)
`dkrinsky@wc.com
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR 2016-00544
`Patent 8,791,154
`
`CERTIFICATE OF SERVICE
`(37 C.F.R. § 42.6(e))
`
`The undersigned hereby certifies that the foregoing document was served on
`
`
`
`
`
`October 27, 2016, by delivering a copy via electronic mail on the following
`
`attorneys of record for the Petitioners:
`
`Michael R. Houston, Ph.D. (Reg. No. 58,486)
`Joseph P. Meara, Ph.D. (Reg. No. 44,932)
`Foley & Lardner LLP, 3000 K St. N.W., Suite 600
`Washington, D.C. 20008
`jmeara-PGP@foley.com
`Counsel for Petitioner Argentum Pharmaceuticals
`
`Teresa Stanek Rea (Reg. No. 30,427)
`Deborah H. Yellin (Reg. No. 45,904)
`Crowell & Moring LLP
`
`
`Intellectual Property Group
`
`1001 Pennsylvania Ave., N.W.
`Washington, D.C. 20004-2595
`TRea@crowell.com
`
`DYellin@Crowell.com
`Counsel for Petitioners Apotex Inc. and Apotex Corp.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/David M. Krinsky/
`David M. Krinsky
`Reg. No. 72,339
`Lead Counsel for Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: October 27, 2016